Major advances have been made in the treatment of visceral leishmaniasis. Studies on efficacy, tolerability and dosages have been completed during the past year for a number of new drugs, mainly lipidic formulations of amphotericin B. No significant progress has, however, been made in the chemotherapy of trypanosomiasis, for which more effective and less toxic drugs are urgently needed.